An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction

New England Journal of Medicine

Volumn 329, Issue 10, 1993, Pages 673-682

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; FIBRINOLYTIC THERAPY; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION;

AGED; CEREBROVASCULAR DISORDERS; COMPARATIVE STUDY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; STREPTOKINASE; SUPPORT, NON-U.S. GOV'T; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0027240597     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199309023291001     Document Type: Article

References (20)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360
3. Topol EJ Which thrombolytic agent should one choose? Prog Cardiovasc Dis 1991; 34: 165-178
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
5. The International Study Group. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-75
6. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1993; 339: 753-770
7. Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
8. Neuhaus KL, Von Essen R, Tebbe U, Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J Am Coll Cardiol 1992; 19: 885-891
9. Carney RJ, Murphy GA, Brandt TR, Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. J Am Coll Cardiol 1992; 20: 17-23
10. Topol EJ, Califf RM, George BS, Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 1988; 77: 1100-1107
11. Califf RM, Topol EJ, Stack RS, Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty in myocardial infarction -- phase 5 randomized trial. Circulation 1991; 83: 1543-1556
12. Grines CL, Nissen SE, Booth DC, A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84: 540-549
13. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990; 323: 1433-1437
14. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-1417
15. de Bono DP, Simoons ML, Tijssen J, Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67: 122-128
16. Granger C, Califf R, Woodlief L, The Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Pilot Study: combined streptokinase and t-PA. Circulation 1991; 84: Suppl II: II-573 abstract.
17. O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556
18. Lan KKG, DeMets DL Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-663
19. Topol EJ, Armstrong P, Van de Werf F, Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol 1992; 19: 1123-1128
20. Lincoff AM, Topol EJ Illusion of reperfusion: does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993; 87: 1792-1805